Developer docs
API playgroundTry for free, no card

Search company profiles

Blank Bio

Full company profile

uuid00063d6

Namestring
Blank Bio
Legal namestring
Blank Bio
Websiteurl
blank.bio
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Blank Bio is an applied AI research company developing RNA foundation models for precision oncology. The company trains foundation models on bulk RNA-seq data — including high-resolution PacBio HiFi long-read sequencing — to capture molecular signals that standard per-gene count pipelines discard, such as isoform architecture and patient-specific tumor biology. Its core product platform centers on these RNA foundation models, supplemented by application modules for disease trajectory modeling (prognostic biomarkers enabling covariate-adjusted trial design) and patient selection (predictive biomarkers identifying likely responders and emerging resistance mechanisms). The company also publishes research artifacts, including the mRNABench benchmarking suite (10 datasets, 59 tasks) and the Orthrus+MLM model (~10M parameter Mamba-based architecture combining contrastive learning with masked language modeling), with prior academic work (Orthrus) published in Nature Methods.

Blank Bio operates a B2B, sales-led go-to-market targeting pharmaceutical and diagnostic companies. Revenue mechanics are not publicly disclosed but are characterized as a partnership/licensing-royalty model: the company works with pharma teams on clinical trial design, patient stratification, and biomarker development, with an early access program accessed via direct email outreach to founders@blank.bio. Pricing is not publicly disclosed and no customer logos, ARR, or contract values are available in the source material.

The company was founded in 2025 and is headquartered in San Francisco. In May 2026 it closed a $7.2 million oversubscribed seed round co-led by Define Ventures, Leonis Capital, SignalFire, and Y Combinator, with participation from Nova Threshold and Ripple Ventures. Concurrently it announced a strategic collaboration with Pacific Biosciences (PacBio) to generate long-read RNA-seq data from up to 100 fresh frozen patient tumor samples (sequenced at Seattle Children's Research Institute using SPTLabtech firefly+ automation). The team is led by CEO and Co-Founder Jonathan Hsu and includes AI scientists and engineers from Recursion, Deep Genomics, DeepMind, and Amazon, and researchers from Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute, with publications in Nature Methods, Nature Genetics, Nature Biotechnology, ICML, and NeurIPS.

Short descriptiontext

Blank Bio builds RNA foundation models that analyze tumor transcriptomes for patient-level prediction in oncology. The company partners with pharmaceutical and diagnostic firms to support clinical trial design, patient stratification, and biomarker discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA foundation models, precision oncology AI, biomarker discovery, clinical trial analytics, bulk RNA sequencing
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology AI
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharma Partnership Model
TypeLicensing Royalties
Description

Blank Bio partners with pharmaceutical companies to provide predictive and prognostic biomarkers for clinical trial design. Revenue likely comes from research collaborations, biomarker development partnerships, and potentially licensing of models or data.

blank.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Blank Bio is an applied AI research lab building RNA foundation models trained on bulk RNA-seq data to capture molecular complexity in tumor transcriptomes (including isoform architecture and patient-specific tumor biology signals). The models support two core applications: disease trajectory modeling, which produces prognostic biomarkers for clinical trial design, and patient selection, which identifies likely therapy responders and emerging resistance mechanisms for pharmaceutical clinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced clinical trial size through covariate adjustment using RNA prognostic scores
+2 more records
Product overview1 text field

Blank Bio is an applied AI research lab offering RNA foundation models as its core product platform. The models learn directly from the molecular complexity of tumor transcriptomes (bulk RNA-seq) to improve patient-level prediction across oncology. The company also develops specialized applications including Disease Trajectory Modeling (prognostic biomarkers) and Patient Selection (predictive biomarkers). Research tools include mRNABench (a benchmarking suite) and Orthrus+MLM (a compact foundation model). All offerings support pharmaceutical companies in making better clinical development decisions, designing more efficient trials, and increasing the odds of therapeutic success.

Product and service3 records
1RNA Foundation Models
CategoryAI Foundation Models
Description

Applied AI foundation models trained on bulk RNA-seq data that capture molecular complexity (isoform architecture, mutational complexity, patient-specific tumor biology signals) to predict disease progression and treatment response for pharmaceutical precision oncology applications. Sold to pharma and diagnostic partners via direct sales and early access program.

2Disease Trajectory Modeling
CategoryPrognostic Biomarker Application
Description

Prognostic biomarker application that predicts how a patient's disease is likely to progress over time using their molecular profile. RNA prognostic scores enable covariate adjustment to help clinical development teams design trials that reach statistical power with fewer patients. Sold to pharmaceutical companies for clinical trial design.

3Patient Selection
CategoryPredictive Biomarker Application
Description

Predictive biomarker application that characterizes biological differences between patients to identify those most likely to respond to a given therapy, as well as emerging resistance mechanisms and potential combination strategies. Sold to pharmaceutical teams for clinical trial enrichment and combination strategy support.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Strategic collaboration to advance RNA foundation models for precision oncology. Blank Bio will generate PacBio HiFi long-read RNA sequencing data from up to 100 fresh frozen patient tumor samples spanning multiple cancer indications. Sequencing is conducted at Seattle Children's Research Institute using Kinnex RNA libraries automated on SPTLabtech firefly+ platform. The data is used to further train and evaluate Blank Bio's foundation models for oncology applications including patient stratification, biomarker discovery, and clinical interpretation.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research institute where PacBio HiFi long-read RNA sequencing is conducted for Blank Bio's collaboration. Kinnex RNA libraries are automated on SPTLabtech firefly+ platform at this location.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI platform for clinical research and oncology that partners with pharma to improve trial design and patient stratification. Directly comparable to Blank Bio's disease trajectory and patient selection applications, though with broader multimodal data and a federated learning approach.

TypeBroad incumbent
Description

Molecular diagnostics company owned by Roche that profiles tumors using DNA and RNA sequencing for clinical decision-making. Comparable as an RNA-seq-enabled diagnostics and pharma services platform, though operating at much larger scale with established reimbursement.

TypeDirect peer
Description

AI-driven RNA therapeutics company using foundation models to predict RNA biology and identify drug targets. Most directly comparable to Blank Bio given its focus on RNA-centric AI, although Deep Genomics focuses on therapeutic development rather than clinical trial biomarker design.

4Tempus Labs
TypeBroad incumbent
Description

AI-powered precision medicine company that analyzes multimodal clinical and molecular data (including RNA-seq) for oncology applications. Comparable in serving pharma with biomarker and patient stratification services, but at much greater scale across DNA, RNA, imaging, and clinical records.

TypeBroad incumbent
Description

Machine learning-driven drug discovery company with partnerships across multiple pharma companies. Comparable as an AI-bio platform serving pharma R&D, but focused on phenotypic screening and target discovery rather than RNA-seq analytics.

TypeEmerging player
Description

RNA cell therapy company developing mRNA-engineered cell therapies for autoimmune disease and cancer. Comparable as an RNA-focused emerging biotech but operates in therapeutics rather than AI/RNA-seq analytics.

TypeEmerging player
Description

Programmable mRNA therapeutics company developing controllable gene expression medicines. Comparable as an RNA-focused emerging biotech leveraging computational biology, though therapeutic-oriented rather than analytics-focused like Blank Bio.

TypeBroad incumbent
Description

Large AI-for-drug-discovery incumbent combining high-throughput biology with machine learning. Comparable as a techbio platform serving pharma customers, though much broader in scope (target ID, phenotypic screening, chemistry) and substantially better capitalized.

TypeOthers
Description

Provider of single-cell and spatial genomics tools that enable high-resolution transcriptomic profiling. Comparable as enabling infrastructure for RNA-based biological discovery, but supplies research tools rather than predictive models or pharma services.

TypeOthers
Description

Long-read sequencing technology provider and Blank Bio's strategic data partner. Comparable as the upstream sequencing platform enabling high-resolution RNA analysis, but operates in sequencing hardware/consumables rather than AI analytics or pharma services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blank Bio

Precision Oncology AIblank.bio

Blank Bio builds RNA foundation models that analyze tumor transcriptomes for patient-level prediction in oncology. The company partners with pharmaceutical and diagnostic firms to support clinical trial design, patient stratification, and biomarker discovery.

What Blank Bio does

Blank Bio is an applied AI research company developing RNA foundation models for precision oncology. The company trains foundation models on bulk RNA-seq data — including high-resolution PacBio HiFi long-read sequencing — to capture molecular signals that standard per-gene count pipelines discard, such as isoform architecture and patient-specific tumor biology. Its core product platform centers on these RNA foundation models, supplemented by application modules for disease trajectory modeling (prognostic biomarkers enabling covariate-adjusted trial design) and patient selection (predictive biomarkers identifying likely responders and emerging resistance mechanisms). The company also publishes research artifacts, including the mRNABench benchmarking suite (10 datasets, 59 tasks) and the Orthrus+MLM model (~10M parameter Mamba-based architecture combining contrastive learning with masked language modeling), with prior academic work (Orthrus) published in Nature Methods.

Blank Bio operates a B2B, sales-led go-to-market targeting pharmaceutical and diagnostic companies. Revenue mechanics are not publicly disclosed but are characterized as a partnership/licensing-royalty model: the company works with pharma teams on clinical trial design, patient stratification, and biomarker development, with an early access program accessed via direct email outreach to founders@blank.bio. Pricing is not publicly disclosed and no customer logos, ARR, or contract values are available in the source material.

The company was founded in 2025 and is headquartered in San Francisco. In May 2026 it closed a $7.2 million oversubscribed seed round co-led by Define Ventures, Leonis Capital, SignalFire, and Y Combinator, with participation from Nova Threshold and Ripple Ventures. Concurrently it announced a strategic collaboration with Pacific Biosciences (PacBio) to generate long-read RNA-seq data from up to 100 fresh frozen patient tumor samples (sequenced at Seattle Children's Research Institute using SPTLabtech firefly+ automation). The team is led by CEO and Co-Founder Jonathan Hsu and includes AI scientists and engineers from Recursion, Deep Genomics, DeepMind, and Amazon, and researchers from Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute, with publications in Nature Methods, Nature Genetics, Nature Biotechnology, ICML, and NeurIPS.

Blank Bio firmographics

Firmographics
Name
Blank Bio
Legal name
Blank Bio
Website
https://blank.bio
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Blank Bio builds RNA foundation models that analyze tumor transcriptomes for patient-level prediction in oncology. The company partners with pharmaceutical and diagnostic firms to support clinical trial design, patient stratification, and biomarker discovery.
Ownership category
akta.pro rank

Blank Bio industry classification

Industry
Product category
Precision Oncology AI
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • RNA foundation models
  • Precision oncology AI
  • Biomarker discovery
  • Clinical trial analytics
  • Bulk RNA sequencing

Where Blank Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Blank Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharma Partnership Model: Blank Bio partners with pharmaceutical companies to provide predictive and prognostic biomarkers for clinical trial design. Revenue likely comes from research collaborations, biomarker development partnerships, and potentially licensing of models or data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Blank Bio product offering

Product offering

Core offering

Blank Bio is an applied AI research lab building RNA foundation models trained on bulk RNA-seq data to capture molecular complexity in tumor transcriptomes (including isoform architecture and patient-specific tumor biology signals). The models support two core applications: disease trajectory modeling, which produces prognostic biomarkers for clinical trial design, and patient selection, which identifies likely therapy responders and emerging resistance mechanisms for pharmaceutical clinical development.

Product overview

Blank Bio is an applied AI research lab offering RNA foundation models as its core product platform. The models learn directly from the molecular complexity of tumor transcriptomes (bulk RNA-seq) to improve patient-level prediction across oncology. The company also develops specialized applications including Disease Trajectory Modeling (prognostic biomarkers) and Patient Selection (predictive biomarkers). Research tools include mRNABench (a benchmarking suite) and Orthrus+MLM (a compact foundation model). All offerings support pharmaceutical companies in making better clinical development decisions, designing more efficient trials, and increasing the odds of therapeutic success.

Differentiator

Problem solved

Functional benefit

Products and services

  • RNA Foundation Models Applied AI foundation models trained on bulk RNA-seq data that capture molecular complexity (isoform architecture, mutational complexity, patient-specific tumor biology signals) to predict disease progression and treatment response for pharmaceutical precision oncology applications. Sold to pharma and diagnostic partners via direct sales and early access program.
  • Disease Trajectory Modeling Prognostic biomarker application that predicts how a patient's disease is likely to progress over time using their molecular profile. RNA prognostic scores enable covariate adjustment to help clinical development teams design trials that reach statistical power with fewer patients. Sold to pharmaceutical companies for clinical trial design.
  • Patient Selection Predictive biomarker application that characterizes biological differences between patients to identify those most likely to respond to a given therapy, as well as emerging resistance mechanisms and potential combination strategies. Sold to pharmaceutical teams for clinical trial enrichment and combination strategy support.

Quantifiable outcome

  • Reduced clinical trial size through covariate adjustment using RNA prognostic scores
  • +2 more outcomes

Companies that use Blank Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Blank Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Blank Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • Pacific Biosciences (PacBio)coreStrategic or Co-development Partner · 19 May 2026Strategic collaboration to advance RNA foundation models for precision oncology. Blank Bio will generate PacBio HiFi long-read RNA sequencing data from up to 100 fresh frozen patient tumor samples spanning multiple cancer indications. Sequencing is conducted at Seattle Children's Research Institute using Kinnex RNA libraries automated on SPTLabtech firefly+ platform. The data is used to further train and evaluate Blank Bio's foundation models for oncology applications including patient stratification, biomarker discovery, and clinical interpretation.
  • Seattle Children's Research InstitutesupportingStrategic or Co-development PartnerResearch institute where PacBio HiFi long-read RNA sequencing is conducted for Blank Bio's collaboration. Kinnex RNA libraries are automated on SPTLabtech firefly+ platform at this location.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Blank Bio competitors and assessment

Company assessment

Direct peers

  • Owkin: AI platform for clinical research and oncology that partners with pharma to improve trial design and patient stratification. Directly comparable to Blank Bio's disease trajectory and patient selection applications, though with broader multimodal data and a federated learning approach.
  • Deep Genomics: AI-driven RNA therapeutics company using foundation models to predict RNA biology and identify drug targets. Most directly comparable to Blank Bio given its focus on RNA-centric AI, although Deep Genomics focuses on therapeutic development rather than clinical trial biomarker design.

Broad incumbents

  • Foundation Medicine: Molecular diagnostics company owned by Roche that profiles tumors using DNA and RNA sequencing for clinical decision-making. Comparable as an RNA-seq-enabled diagnostics and pharma services platform, though operating at much larger scale with established reimbursement.
  • Tempus Labs: AI-powered precision medicine company that analyzes multimodal clinical and molecular data (including RNA-seq) for oncology applications. Comparable in serving pharma with biomarker and patient stratification services, but at much greater scale across DNA, RNA, imaging, and clinical records.
  • Insitro: Machine learning-driven drug discovery company with partnerships across multiple pharma companies. Comparable as an AI-bio platform serving pharma R&D, but focused on phenotypic screening and target discovery rather than RNA-seq analytics.
  • Recursion Pharmaceuticals: Large AI-for-drug-discovery incumbent combining high-throughput biology with machine learning. Comparable as a techbio platform serving pharma customers, though much broader in scope (target ID, phenotypic screening, chemistry) and substantially better capitalized.

Emerging players

  • Cartesian Therapeutics: RNA cell therapy company developing mRNA-engineered cell therapies for autoimmune disease and cancer. Comparable as an RNA-focused emerging biotech but operates in therapeutics rather than AI/RNA-seq analytics.
  • Strand Therapeutics: Programmable mRNA therapeutics company developing controllable gene expression medicines. Comparable as an RNA-focused emerging biotech leveraging computational biology, though therapeutic-oriented rather than analytics-focused like Blank Bio.

Others

  • 10x Genomics: Provider of single-cell and spatial genomics tools that enable high-resolution transcriptomic profiling. Comparable as enabling infrastructure for RNA-based biological discovery, but supplies research tools rather than predictive models or pharma services.
  • Pacific Biosciences (PacBio): Long-read sequencing technology provider and Blank Bio's strategic data partner. Comparable as the upstream sequencing platform enabling high-resolution RNA analysis, but operates in sequencing hardware/consumables rather than AI analytics or pharma services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Blank Bio social profiles

Digital presence

Blank Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blank Bio leadership team

Management profile

Number of profiles

Profiles1 record

Blank Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blank Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blank Bio

What does Blank Bio do?

Blank Bio is an applied AI research lab building RNA foundation models trained on bulk RNA-seq data to capture molecular complexity in tumor transcriptomes (including isoform architecture and patient-specific tumor biology signals). The models support two core applications: disease trajectory modeling, which produces prognostic biomarkers for clinical trial design, and patient selection, which identifies likely therapy responders and emerging resistance mechanisms for pharmaceutical clinical development.

Is Blank Bio a public or private company?

Blank Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Blank Bio founded?

Blank Bio was founded in 2025. It employs 1 to 10 people.

Where is Blank Bio based?

Blank Bio is headquartered in San Francisco, United States, in the North America region.

How does Blank Bio make money?

One revenue line is on record: pharma Partnership Model.

Who are Blank Bio's main competitors?

Direct peers on record are Owkin and Deep Genomics. Broad incumbents are Foundation Medicine, Tempus Labs, Insitro and Recursion Pharmaceuticals. Emerging players are Cartesian Therapeutics and Strand Therapeutics. Others are 10x Genomics and Pacific Biosciences (PacBio).

Does Blank Bio have an API?

No public API is recorded for Blank Bio.

What industry is Blank Bio in?

Blank Bio's product category is Precision Oncology AI. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WowtaleRNA Foundation model BlankBio, Claude's 'destructive hypothesis' can.San Francisco-based AI biotech startup Blank Bio has developed a foundation model called Ladon, trained on 20 years of bulk RNA sequencing data, which maps biological states to enable researchers to find connections across different experimental contexts without relying on text-based searches. The company integrated Ladon with Anthropic's Claude AI agent via an embedding search MCP, which successfully generated a novel hypothesis about cellular senescence in ME/CFS patients — a mechanism independently evaluated as promising by domain experts. Blank Bio raised $7.2 million in an oversubscribed seed round in May, with participation from Y Combinator, SignalFire, Define Ventures, and others, and simultaneously formed a strategic partnership with PacBio for precision oncology RNA foundation model development.Pulse 2.0Blank Bio: $7.2 Million Seed Raised To Advance RNA Foundation Models For Precision OncologyBlank Bio announced the closing of a $7.2 million seed financing round alongside a strategic collaboration with PacBio to advance RNA foundation models for precision oncology applications. The funding will support model development, expanded pharmaceutical and diagnostic partnerships, and the generation of long-read RNA sequencing datasets from up to 100 patient tumor samples spanning multiple cancer indications, with sequencing work conducted at Seattle Children’s Research Institute. The company’s foundation models are designed to capture molecular complexity including isoform architecture and patient-specific tumor biology signals that are typically lost in traditional RNA-seq analysis pipelines.citybizBlank Bio Raises $7.2M and Partners With PacBio to Build RNA Foundation Models for Precision OncologyBlank Bio has raised $7.2 million in seed funding and formed a partnership with PacBio to develop RNA foundation models for oncology. The collaboration provides access to long-read sequencing data to improve the analysis of tumor transcriptomes.FinSMEsBlank Bio Raises $7.2M in Seed FundingBlank Bio, a San Francisco AI lab training foundation models for RNA, raised $7.2M in seed funding from Define Ventures, Leonis Capital, and others. The company will use the funds for model development, collaborations with pharma and diagnostic firms, and new long-read RNA-seq datasets for biomarkers and diagnostics.Pulse 2.0Blank Bio: $7.2 Million Seed Financing Raised To Advance RNA Foundation Models For Precision OncologyBlank Bio, an AI research lab focusing on RNA foundation models for oncology, completed a $7.2 million seed financing round and formed a strategic collaboration with Pacific Biosciences. The funding will support model development, collaborations, and data generation from long-read RNA sequencing in tumor samples. The collaboration aims to enhance predictive and diagnostic tools in precision oncology using high-resolution RNA data.Business Wire BlogBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision OncologyBlank Bio announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (PacBio) to advance RNA foundation models for precision oncology. Under the collaboration, Blank Bio will generate PacBio HiFi long-read RNA sequencing data from up to 100 fresh frozen patient tumor samples spanning multiple cancer indications, using the data to train and evaluate its foundation models for oncology applications. The funding round, oversubscribed and co-led by Define Ventures, Leonis Capital, SignalFire, and Y Combinator among others, will support continued model development and expanded partnerships with pharmaceutical and diagnostic companies.Stock TitanBlank Bio raises $7.2M, inks PacBio RNA dealBlank Bio announced the closing of a $7.2 million seed financing round and entered a strategic collaboration with PacBio to advance RNA foundation models for precision oncology. Under the collaboration, Blank Bio will generate PacBio HiFi long-read RNA sequencing data from up to 100 fresh frozen patient tumor samples spanning multiple cancer indications, using the data to further train and evaluate its models for improved patient stratification and biomarker discovery.Venture Capital Access OnlineBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision OncologyBlank Bio closed a $7.2 million seed financing and a strategic collaboration with PacBio to advance RNA foundation models for precision oncology. The collaboration will generate long-read bulk RNA-seq data from up to 100 patient tumor samples to train and evaluate the models. Proceeds will support model development, expanded partnerships, and new datasets.PharmiWeb.comPharmiWeb.com – Thank youPharmiWeb.com is closing after 28 years, having operated since 1998. The company thanks members, advertisers, partners, and readers for their contributions. It notes the site was among the first in the dot-com era.BlankBlank Bio Announces Seed Financing and Strategic Collaboration with PacBioBlank Bio closed a $7.2 million seed financing and announced a strategic collaboration with PacBio. The collaboration will generate PacBio HiFi long-read bulk RNA-seq data from up to 100 fresh frozen patient tumor samples. Proceeds will support model development, expanded partnerships, and new datasets for oncology applications.